JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 4151.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Kyowa Kirin Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 15.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Kyowa Kirin Co., Ltd.’s forward annual dividend is ¥70 per share, paid semi-annual. The forward yield is 2.84% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Kyowa Kirin Co., Ltd.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of ¥40. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kyowa Kirin Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 1, 2025 | ¥12-54.88% vs estimate | ¥104.73B-16.85% vs estimate |
|---|
| Q4 2024 | Feb 5, 2025 | ¥8-73.45% vs estimate | ¥132.76B+11.56% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | ¥34-2.55% vs estimate | ¥129.82B+2.21% vs estimate |
|---|
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥2,754+¥137 (+5.21%)
Daiichi Sankyo Company, Limited’s quoted price sits in the lower half of its reported 52-week range, 30.19% below the high.
¥2,571+¥58 (+2.31%)
Astellas Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.37% below the high.
¥3,012+¥23 (+0.77%)
Shionogi & Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
¥5,052+¥78 (+1.57%)
Eisai Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 3.64% below the high.
¥2,256+¥32 (+1.42%)
Ono Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.65% below the high.
¥1,885-¥61 (-3.11%)
Sumitomo Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.69% below the high.
¥3,436+¥18 (+0.53%)
Nippon Shinyaku Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.37% below the high.
